Emiel F. M. Wouters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emiel F. M. Wouters has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Mieke A. Dentener
Department of Respiratory Medicine, University Hospital Maastricht, Maastrict, The Netherlands
2 shared publications- Mieke A. Dentener
Department of Respiratory Medicine, Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University Medical Centre, Maastricht, The Netherlands
2 shared publications - Alvar Agustí
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
1 shared publication - Bartolome R. Celli
Pulmonary and Critical Care Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
1 shared publication - Bruce E. Miller
GlaxoSmithKline, King Of Prussia, PA, USA
1 shared publication - Chris van Weel
Department of Primary and Community Care, Radboud University medical center, Nijmegen, the Netherlands
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 10 September 2010
- Published by Springer Nature in Respiratory Research
- Vol. 11 (1) , 122
Characterisation of COPD heterogeneity in the ECLIPSE cohort
Chronic obstructive pulmonary disease (COPD) is a complex condition with pulmonary and extra-pulmonary manifestations. This study describes the heterogeneity of COPD in a large and well characterised and controlled COPD cohort (ECLIPSE). We studied 2164 clinically stable COPD patients, 337 smokers with normal lung function and 245 never smokers. In these individuals, we measured clinical parameters, nutritional status, spirometry, exercise tolerance, and amount of emphysema by computed tomography. COPD patients were slightly older than controls and had more pack years of smoking than smokers with normal lung function. Co-morbidities were more prevalent in COPD patients than in controls, and occurred to the same extent irrespective of the GOLD stage. The severity of airflow limitation in COPD patients was poorly related to the degree of breathlessness, health status, presence of co-morbidity, exercise capacity and number of exacerbations reported in the year before the study. The distribution of these variables within each GOLD stage was wide. Even in subjects with severe airflow obstruction, a substantial proportion did not report symptoms, exacerbations or exercise limitation. The amount of emphysema increased with GOLD severity. The prevalence of bronchiectasis was low (4%) but also increased with GOLD stage. Some gender differences were also identified. The clinical manifestations of COPD are highly variable and the degree of airflow limitation does not capture the heterogeneity of the disease.
- 10 September 2010
- Published by Springer Nature in Respiratory Research
- Vol. 11 (1) , 122
Top Cited PapersOpen AccessCharacterisation of COPD heterogeneity in the ECLIPSE cohort
Chronic obstructive pulmonary disease (COPD) is a complex condition with pulmonary and extra-pulmonary manifestations. This study describes the heterogeneity of COPD in a large and well characterised and controlled COPD cohort (ECLIPSE). We studied 2164 clinically stable COPD patients, 337 smokers with normal lung function and 245 never smokers. In these individuals, we measured clinical parameters, nutritional status, spirometry, exercise tolerance, and amount of emphysema by computed tomography. COPD patients were slightly older than controls and had more pack years of smoking than smokers with normal lung function. Co-morbidities were more prevalent in COPD patients than in controls, and occurred to the same extent irrespective of the GOLD stage. The severity of airflow limitation in COPD patients was poorly related to the degree of breathlessness, health status, presence of co-morbidity, exercise capacity and number of exacerbations reported in the year before the study. The distribution of these variables within each GOLD stage was wide. Even in subjects with severe airflow obstruction, a substantial proportion did not report symptoms, exacerbations or exercise limitation. The amount of emphysema increased with GOLD severity. The prevalence of bronchiectasis was low (4%) but also increased with GOLD stage. Some gender differences were also identified. The clinical manifestations of COPD are highly variable and the degree of airflow limitation does not capture the heterogeneity of the disease.
- Open Access
- 9 March 2009
- Published by Springer Nature in BMC Medical Genetics
- Vol. 10 (1) , 23
IL6 and CRPhaplotypes are associated with COPD risk and systemic inflammation: a case-control study
Elevated circulating levels of C-reactive protein (CRP), interleukin (IL)-6 and fibrinogen (FG) have been repeatedly associated with many adverse outcomes in patients with chronic obstructive pulmonary disease (COPD). To date, it remains unclear whether and to what extent systemic inflammation is primary or secondary in the pathogenesis of COPD.
- 9 March 2009
- Published by Springer Nature in BMC Medical Genetics
- Vol. 10 (1) , 23
Open AccessIL6 and CRPhaplotypes are associated with COPD risk and systemic inflammation: a case-control study
Elevated circulating levels of C-reactive protein (CRP), interleukin (IL)-6 and fibrinogen (FG) have been repeatedly associated with many adverse outcomes in patients with chronic obstructive pulmonary disease (COPD). To date, it remains unclear whether and to what extent systemic inflammation is primary or secondary in the pathogenesis of COPD.
- Open Access
- 6 May 2008
- Published by Springer Nature in BMC Palliative Care
- Vol. 7 (1) , 5
Self-perceived symptoms and care needs of patients with severe to very severe chronic obstructive pulmonary disease, congestive heart failure or chronic renal failure and its consequences for their closest relatives: the research protocol
Recent research shows that the prevalence of patients with very severe chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF) and chronic renal failure (CRF) continues to rise over the next years. Scientific studies concerning self-perceived symptoms and care needs in patients with severe to very severe COPD, CHF and CRF are scarce.
- 6 May 2008
- Published by Springer Nature in BMC Palliative Care
- Vol. 7 (1) , 5
Open AccessSelf-perceived symptoms and care needs of patients with severe to very severe chronic obstructive pulmonary disease, congestive heart failure or chronic renal failure and its consequences for their closest relatives: the research protocol
Recent research shows that the prevalence of patients with very severe chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF) and chronic renal failure (CRF) continues to rise over the next years. Scientific studies concerning self-perceived symptoms and care needs in patients with severe to very severe COPD, CHF and CRF are scarce.
- 1 December 2007
- Published by Oxford University Press (OUP) in Proceedings of the American Thoracic Society
- Vol. 4 (8) , 626-634
Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of Exacerbations
The systemic manifestations of chronic obstructive pulmonary disease (COPD) exacerbations are recognized, but our understanding of their etiology and importance is lacking largely due to the small number of systematic and longitudinal studies. Most of the systemic manifestations are likely the result of inflammatory processes. Serum biomarkers, such as various cytokines, adipokines, C-reactive protein, and coagulation factors, are elevated during exacerbations. Our understanding of the systemic manifestations can be greatly enhanced if we integrate what is known about the basic science of systemic mediators with the translational science of their role in COPD exacerbations. Many overlapping connections and promising avenues of future research come to light with such a viewpoint.
- 1 December 2007
- Published by Oxford University Press (OUP) in Proceedings of the American Thoracic Society
- Vol. 4 (8) , 626-634
Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of Exacerbations
The systemic manifestations of chronic obstructive pulmonary disease (COPD) exacerbations are recognized, but our understanding of their etiology and importance is lacking largely due to the small number of systematic and longitudinal studies. Most of the systemic manifestations are likely the result of inflammatory processes. Serum biomarkers, such as various cytokines, adipokines, C-reactive protein, and coagulation factors, are elevated during exacerbations. Our understanding of the systemic manifestations can be greatly enhanced if we integrate what is known about the basic science of systemic mediators with the translational science of their role in COPD exacerbations. Many overlapping connections and promising avenues of future research come to light with such a viewpoint.
- Top Cited Papers
Systemic Effects of Smoking
- Open Access
- 1 January 2007
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 5 (1) , 10
Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial
Asthma is a chronic lung disease in which recurrent asthma symptoms create a substantial burden to individuals and their families. At the same time the economic burden associated with asthma is considerable.
- 1 January 2007
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 5 (1) , 10
Open AccessCost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial
Asthma is a chronic lung disease in which recurrent asthma symptoms create a substantial burden to individuals and their families. At the same time the economic burden associated with asthma is considerable.
- Open Access
- 1 June 2006
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 6 (1) , 11
Patterns of inflammation and the use of reversibility testing in smokers with airway complaints
Background: Although both smoking and respiratory complaints are very common, tools to improve diagnostic accuracy are scarce in primary care. This study aimed to reveal what inflammatory patterns prevail in clinically established diagnosis groups, and what factors are associated with eosinophilia.Method: Induced sputum and blood plasma of 59 primary care patients with COPD (n = 17), asthma (n = 11), chronic bronchitis (CB, n = 14) and smokers with no respiratory complaints ('healthy smokers', n = 17) were collected, as well as lung function, smoking history and clinical work-up. Patterns of inflammatory markers per clinical diagnosis and factors associated with eosinophilia were analyzed by multiple regression analyses, the differences expressed in odds ratios (OR) with 95% confidence intervals.Results: Multivariately, COPD was significantly associated with raised plasma-LBP (OR 1.2 [1.04–1.37]) and sTNF-R55 in sputum (OR 1.01 [1.001–1.01]), while HS expressed significantly lowered plasma-LBP (OR 0.8 [0.72–0.95]). Asthma was characterized by higher sputum eosinophilic counts (OR 1.3 [1.05–1.54]), while CB showed a significantly higher proportion of sputum lymphocytic counts (OR 1.5 [1.12–1.9]). Sputum eosinophilia was significantly associated with reversibility after adjusting for smoking, lung function, age, gender and allergy.Conclusion: Patterns of inflammatory markers in a panel of blood plasma and sputum cells and mediators were discernable in clinical diagnosis groups of respiratory disease. COPD and so-called healthy smokers showed consistent opposite associations with plasma LBP, while chronic bronchitics showed relatively predominant lymphocytic inflammation compared to other diagnosis groups. Only sputum eosinophilia remained significantly associated with reversibility across the spectrum of respiratory disease in smokers with airway complaints.
- 1 June 2006
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 6 (1) , 11
Open AccessPatterns of inflammation and the use of reversibility testing in smokers with airway complaints
Background: Although both smoking and respiratory complaints are very common, tools to improve diagnostic accuracy are scarce in primary care. This study aimed to reveal what inflammatory patterns prevail in clinically established diagnosis groups, and what factors are associated with eosinophilia.Method: Induced sputum and blood plasma of 59 primary care patients with COPD (n = 17), asthma (n = 11), chronic bronchitis (CB, n = 14) and smokers with no respiratory complaints ('healthy smokers', n = 17) were collected, as well as lung function, smoking history and clinical work-up. Patterns of inflammatory markers per clinical diagnosis and factors associated with eosinophilia were analyzed by multiple regression analyses, the differences expressed in odds ratios (OR) with 95% confidence intervals.Results: Multivariately, COPD was significantly associated with raised plasma-LBP (OR 1.2 [1.04–1.37]) and sTNF-R55 in sputum (OR 1.01 [1.001–1.01]), while HS expressed significantly lowered plasma-LBP (OR 0.8 [0.72–0.95]). Asthma was characterized by higher sputum eosinophilic counts (OR 1.3 [1.05–1.54]), while CB showed a significantly higher proportion of sputum lymphocytic counts (OR 1.5 [1.12–1.9]). Sputum eosinophilia was significantly associated with reversibility after adjusting for smoking, lung function, age, gender and allergy.Conclusion: Patterns of inflammatory markers in a panel of blood plasma and sputum cells and mediators were discernable in clinical diagnosis groups of respiratory disease. COPD and so-called healthy smokers showed consistent opposite associations with plasma LBP, while chronic bronchitics showed relatively predominant lymphocytic inflammation compared to other diagnosis groups. Only sputum eosinophilia remained significantly associated with reversibility across the spectrum of respiratory disease in smokers with airway complaints.
- 1 May 2006
- Published by Oxford University Press (OUP) in Proceedings of the American Thoracic Society
- Vol. 3 (3) , 262-269
Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several?
Health outcomes represent a broad group of endpoints used in clinical practice to assess the efficacy and effectiveness of interventions and to assess disease outcomes. Health status is one of the widely applied patient-reported health outcomes. The outcome of a variety of interventions, targeting local impairment or local airway inflammation, is evaluated by health status measurements; these global or summative outcomes indeed quantify the overall effect of a number of biological processes. Targeting the systemic compartment to improve health status is already widely applied in the domain of pulmonary rehabilitation. Challenging developments targeting systemic inflammation and biological processes related to systemic inflammation are particularly addressed in this review.
- 1 May 2006
- Published by Oxford University Press (OUP) in Proceedings of the American Thoracic Society
- Vol. 3 (3) , 262-269
Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several?
Health outcomes represent a broad group of endpoints used in clinical practice to assess the efficacy and effectiveness of interventions and to assess disease outcomes. Health status is one of the widely applied patient-reported health outcomes. The outcome of a variety of interventions, targeting local impairment or local airway inflammation, is evaluated by health status measurements; these global or summative outcomes indeed quantify the overall effect of a number of biological processes. Targeting the systemic compartment to improve health status is already widely applied in the domain of pulmonary rehabilitation. Challenging developments targeting systemic inflammation and biological processes related to systemic inflammation are particularly addressed in this review.
- Open Access
- 1 October 2005
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 2 (4) , 177-179
Pulmonary rehabilitation and integrated care
- 1 October 2005
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 2 (4) , 177-179
Open AccessPulmonary rehabilitation and integrated care